Breaking News Instant updates and real-time market news.

VRX

Valeant

$22.24

-0.53 (-2.33%)

12:55
10/14/16
10/14
12:55
10/14/16
12:55

Valeant announces price raises of 2%-9% in certain portfolios

Valeant Pharmaceuticals announced that the company's Patient Access and Pricing Committee has made decisions regarding price changes of products in the company's neurology, GI and urology portfolios. The planned wholesale acquisition price changes, effective October 14, range from 2% to 9%. "The changes are aligned with the Committee's commitment that the average annual price increase for Valeant's prescription pharmaceutical products will be set at no greater than single digits and below the 5-year weighted average of the increases within the branded biopharmaceutical industry," the company said in a statement. Valeant added that its 2016 pricing actions across its U.S. branded Rx portfolio, represent an increase of less than 2.0% within the calendar 2016 year. On a forward looking annualized basis, 2016 price actions are in line with 2016 Consumer Price Index of 2.3%, it explained. "In 2016, net pricing of Valeant's Dermatology and Ophthalmology products, after taking into account the impact of rebates and other adjustments, will have decreased by greater than 10% on average. There will be no pricing adjustments this year on Dermatology and Ophthalmology products," Valeant stated. Joseph Papa, Valeant CEO, said, "In reviewing product pricing, the Committee considers overall market dynamics along with the impact of any price increase on patients, doctors, and our health care industry partners. We believe the actions announced today are consistent with our commitment to ensure that patients continue to have access to the medicines they need at an affordable price and demonstrate that we are taking our approach to responsible pricing seriously."

  • 16

    Nov

  • 14

    Dec

VRX Valeant
$22.24

-0.53 (-2.33%)

09/19/16
WELS
09/19/16
NO CHANGE
WELS
Price increases could be negative sign, says Wells Fargo
After Valeant increased the list prices of three of its products with combined sales of $1.2M last year, Wells Fargo says further price increases could be forthcoming, and the price increases could indicate that the company feels it needs to raise prices to meet its 2H16 guidance. Noting that the company raised the list price on each of the products by 9.9%, Wells believes that the company could have raised prices by that amount instead of 10% to "stay under the radar of managed care plans and states" looking to prevent double digit price increases. Wells keeps an Underperform rating on the stock.
09/20/16
DBAB
09/20/16
INITIATION
Target $30
DBAB
Hold
Valeant reinstated with a Hold at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert reinstated coverage of Valeant Pharmaceuticals with a Hold rating and $30 price target. Potential fines from the numerous investigations into the company are difficult to predict, Gilbert tells investors in a research note. The analyst assumes revenue for Valeant's dermatology business will begin to rebound in the second half of 2016 and into 2017. Before restricting coverage on the name, Deutsche had a Hold rating on the shares.
09/23/16
WELS
09/23/16
NO CHANGE
WELS
Underperform
Wells thinks Valeant's $1B acquisition in 2015 could be worth $50M or less
Wells Fargo analyst David Maris believes Valeant Pharmaceuticals will take a large impairment charge on the carrying value of Sprout, perhaps as much as 90% of its value. Sprout won approval in 2015 for Addyi, the first pill to aid a woman's sex drive. Valeant bought Sprout for $1B in August 2015, and in December 2015 forecasted sales of $100M-$150M, Maris points out. With sales in July, according to IMS, reaching only $696,235, Maris thinks Addyi "has no chance" of reaching $100M in 2016 and "might not even reach" $10M. He believes Sprout may be worth $50M or less. Without an add-back to adjusted earnings going forward, the [potential write-off would have a 14c per share impact to annual adjusted earnings in 2017 and beyond, Maris tells investors in a research note. Further, he believes Valeant could have other assets with this same problem, compounding the company's divestiture plans. Maris keeps an Underperform rating on Valeant with a $17-$22 price target range. The drugmaker closed yesterday down 12c to $26.85.
10/03/16
WELS
10/03/16
NO CHANGE
WELS
Underperform
Valeant legal woes may present bigger risk than realized, says Wells Fargo
Wells Fargo analyst David Maris said in a new note to investors that he continues to think investors are underestimating the potential downside posed by Valeant's legal troubles, whose stakes "might not be in the tens of millions, but much larger." Maris, who has kept an Underperform rating on Valeant Pharmaceuticals (VRX) since starting coverage of the stock in February, notes that the company has not taken any reserves for Allergan (AGN) or Philidor-related litigation.

TODAY'S FREE FLY STORIES

ADNT

Adient

$81.91

-0.51 (-0.62%)

05:54
01/17/18
01/17
05:54
01/17/18
05:54
Downgrade
Adient rating change  »

Adient downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

AEP

American Electric

$67.50

0.04 (0.06%)

05:53
01/17/18
01/17
05:53
01/17/18
05:53
Upgrade
American Electric rating change  »

American Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$116.64

-1.53 (-1.29%)

05:53
01/17/18
01/17
05:53
01/17/18
05:53
Downgrade
PPG rating change  »

PPG downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

NBR

Nabors Industries

$8.23

0.04 (0.49%)

05:52
01/17/18
01/17
05:52
01/17/18
05:52
Downgrade
Nabors Industries rating change  »

Nabors Industries resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

ETH

Ethan Allen

$28.15

-0.5 (-1.75%)

05:52
01/17/18
01/17
05:52
01/17/18
05:52
Downgrade
Ethan Allen rating change  »

Ethan Allen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

QTS

QTS Realty Trust

$52.47

0.82 (1.59%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Downgrade
QTS Realty Trust rating change  »

QTS Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQ

La Quinta

$18.44

-0.03 (-0.16%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Upgrade
La Quinta rating change  »

La Quinta upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASND

Ascendis Pharma

$47.60

1.02 (2.19%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Recommendations
Ascendis Pharma analyst commentary  »

Ascendis Pharma price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLX

Shell Midstream

$30.74

0.21 (0.69%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Downgrade
Shell Midstream rating change  »

Shell Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

ENR

Energizer

$59.11

7.49 (14.51%)

05:47
01/17/18
01/17
05:47
01/17/18
05:47
Downgrade
Energizer rating change  »

Energizer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 31

    Jan

ABB

ABB

$28.07

-0.02 (-0.07%)

05:46
01/17/18
01/17
05:46
01/17/18
05:46
Upgrade
ABB rating change  »

ABB upgraded to Hold from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CELG

Celgene

$104.82

-1.18 (-1.11%)

, JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

05:45
01/17/18
01/17
05:45
01/17/18
05:45
Recommendations
Celgene, Juno Therapeutics analyst commentary  »

Jefferies believes $8B…

CELG

Celgene

$104.82

-1.18 (-1.11%)

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

DF

Dean Foods

$11.28

0.01 (0.09%)

05:45
01/17/18
01/17
05:45
01/17/18
05:45
Upgrade
Dean Foods rating change  »

Dean Foods upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$176.19

-0.9 (-0.51%)

05:44
01/17/18
01/17
05:44
01/17/18
05:44
Downgrade
Apple rating change  »

Apple downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

RGC

Regal Entertainment

$22.90

-0.07 (-0.30%)

05:43
01/17/18
01/17
05:43
01/17/18
05:43
Downgrade
Regal Entertainment rating change  »

Regal Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PII

Polaris Industries

$127.90

-2.13 (-1.64%)

05:43
01/17/18
01/17
05:43
01/17/18
05:43
Upgrade
Polaris Industries rating change  »

Polaris Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

DISH

Dish

$47.99

-1.49 (-3.01%)

05:42
01/17/18
01/17
05:42
01/17/18
05:42
Downgrade
Dish rating change  »

Dish downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

LBTYA

Liberty Global

$36.56

-0.31 (-0.84%)

05:42
01/17/18
01/17
05:42
01/17/18
05:42
Upgrade
Liberty Global rating change  »

Liberty Global upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IR

Ingersoll-Rand

$90.26

-0.84 (-0.92%)

, MIELY

Mitsubishi Electric

$36.44

0.035 (0.10%)

05:42
01/17/18
01/17
05:42
01/17/18
05:42
Hot Stocks
Ingersoll-Rand, Mitsubishi Electric establish JV for ductless and VRF systems »

Ingersoll-Rand (IR) and…

IR

Ingersoll-Rand

$90.26

-0.84 (-0.92%)

MIELY

Mitsubishi Electric

$36.44

0.035 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

EGHT

8x8, Inc.

$15.30

0.05 (0.33%)

05:42
01/17/18
01/17
05:42
01/17/18
05:42
Upgrade
8x8, Inc. rating change  »

8x8, Inc. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 25

    Jan

NVS

Novartis

$86.73

0.08 (0.09%)

05:38
01/17/18
01/17
05:38
01/17/18
05:38
Hot Stocks
Novartis granted FDA priority review for Kymriah »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 08

    Feb

  • 16

    Feb

  • 23

    Apr

  • 17

    May

SKX

Skechers

$37.91

-0.64 (-1.66%)

05:38
01/17/18
01/17
05:38
01/17/18
05:38
Recommendations
Skechers analyst commentary  »

Skechers price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$100.69

-0.18 (-0.18%)

05:36
01/17/18
01/17
05:36
01/17/18
05:36
Hot Stocks
Walmart launches opioid disposal solution »

In an effort to help curb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

BLL

Ball Corp.

$38.39

0.49 (1.29%)

05:35
01/17/18
01/17
05:35
01/17/18
05:35
Upgrade
Ball Corp. rating change  »

Ball Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

PBYI

Puma Biotechnology

$90.85

-8.4 (-8.46%)

05:34
01/17/18
01/17
05:34
01/17/18
05:34
Recommendations
Puma Biotechnology analyst commentary  »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.